NASDAQ · ACRS
Healthcare · Medical - Diagnostics & Research
$5.32
Down-$0.21 (-3.71%)
Updated Sep 17, 2026, 8:45 AM
SID Score
6.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ACRS closed at $5.32 after 20 trading sessions, down 17.39% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $5.54 | $5.56 | $4.975 | $5.32 | 5.77M |
| Sep 15, 2026 | $5.60 | $5.62 | $5.405 | $5.525 | 1.33M |
| Sep 14, 2026 | $5.29 | $5.715 | $5.29 | $5.64 | 5.84M |
| Sep 11, 2026 | $5.50 | $5.595 | $5.17 | $5.32 | 3.28M |
| Sep 10, 2026 | $5.55 | $5.555 | $5.385 | $5.505 | 2.21M |
| Sep 9, 2026 | $6.075 | $6.075 | $5.41 | $5.56 | 3.68M |
| Sep 8, 2026 | $6.08 | $6.145 | $5.915 | $6.06 | 3.06M |
| Sep 4, 2026 | $5.965 | $6.195 | $5.87 | $6.17 | 1.75M |
| Sep 3, 2026 | $6.24 | $6.27 | $5.895 | $5.95 | 1.39M |
| Sep 2, 2026 | $6.09 | $6.24 | $5.875 | $6.18 | 1.55M |
| Sep 1, 2026 | $6.09 | $6.24 | $5.95 | $6.02 | 1.49M |
| Aug 31, 2026 | $5.97 | $6.06 | $5.845 | $6.05 | 1.63M |
| Aug 28, 2026 | $6.10 | $6.18 | $5.95 | $6.01 | 1.22M |
| Aug 27, 2026 | $6.15 | $6.305 | $6.12 | $6.16 | 1.41M |
| Aug 26, 2026 | $6.53 | $6.53 | $6.07 | $6.19 | 1.74M |
| Aug 25, 2026 | $6.36 | $6.5999 | $6.15 | $6.535 | 3.35M |
| Aug 24, 2026 | $6.35 | $6.40 | $6.02 | $6.31 | 1.27M |
| Aug 21, 2026 | $6.36 | $6.50 | $6.29 | $6.41 | 2.21M |
| Aug 20, 2026 | $6.35 | $6.46 | $6.17 | $6.33 | 1.51M |
| Aug 19, 2026 | $6.40 | $6.4487 | $6.20 | $6.44 | 2.07M |
The latest Smart Investors Daily articles mentioning ACRS.
ACRS research
Company profile and research snapshot.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 1, 2026 | Canaccord Genuity | Buy | — |
| Jun 2, 2026 | LifeSci Capital | Outperform | — |
| May 5, 2026 | Piper Sandler | Overweight | — |
| May 5, 2026 | Guggenheim | Buy | — |
| Apr 29, 2026 | Wedbush | Outperform | — |
No generated briefing is available yet.
Benzinga · Mar 20, 2026
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that an ePoster on the results from
Benzinga · Mar 19, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and maintains $16 price target.
Benzinga · Mar 18, 2026
Yahoo · Feb 26, 2026
Executives from Aclaris Therapeutics (NASDAQ:ACRS) outlined the company’s clinical-stage pipeline and upcoming catalysts during a presentation at Oppenheimer’s Annual Healthcare Conference, emphasizing programs in inflammatory and immunological diseases spanning monoclonal antibodies, a bispecific a
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ACRS.
